Abstract:Colorectal cancer (CRC) is a malignant tumour with high morbidity and mortality worldwide. Efficient screening strategies for CRC and pre-cancerous lesions can promote early medical intervention and treatment, thereby reducing morbidity and mortality. Proteins are generally considered key biomarkers of cancer. Herein, we performed a quantitative, original-tissue proteomics study in a cohort of ninety patients from pre-cancerous to cancerous conditions via liquid chromatography-tandem mass spectrometry. In total, 134,812 peptides, 8697 proteins, 2355 union differentially expressed proteins (DEPs), and 409 shared DEPs (compared with adjacent tissues) were identified. The number of DEPs indicated a positive correlation with increasing severity of illness. The union and shared DEPs were both enriched in the KEGG pathway of focal adhesion, metabolism of xenobiotics by cytochrome P450, and drug metabolism by cytochrome P450. Among the 2355 union DEPs, 32 were selected for identification and validation by multiple reaction monitoring from twenty plasma specimens. Of these, three proteins, transferrin receptor protein 1 (TFR1), adenosylhomocysteinase (SAHH), and immunoglobulin heavy variable 3-7 (HV307), were significantly differentially expressed and displayed the same expression pattern in plasma as observed in the tissue data. In conclusion, TFR1, SAHH, and HV307 may be considered as potential biomarkers for CRC screening. SIGNIFICANCE: Although CRC is a malignant tumour with high morbidity and mortality worldwide, efficient screening strategies for CRC and pre-cancerous lesions can play an important role in addressing these issues. Screening of molecular biomarkers provide a non-invasive, cost-effective, and efficient approach. Proteins are generally considered key molecular biomarkers of cancer. Our study reports a quantitative proteomics analysis of protein biomarkers for colorectal cancer (CRC) and adenomatous polyps, and identifies TFR1, SAHH, and HV307 as potential biomarkers for screening. This research makes a significant contribution to the literature as although mass spectrometry-based proteomics research has been widely used for clinical research, its application to clinical translation as parallel specimens ranging from pre-cancerous to cancerous tissues-according to the degree of disease progression-has not been readily assessed.

Identification of Serum Biomarkers for Colorectal Cancer Metastasis Using A Differential Secretome Approach

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

Identification of Differentially Expressed Proteins in Colorectal Cancer by Proteomics: Down-regulation of Secretagogin

Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues.

Proteomic research of biomarker of colorectal cancer metastasis

Research on the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer using SELDI-TOF-MS

Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS.

Comparative proteomic study for profiling differentially expressed proteins between Chinese left- and right-sided colon cancers.

Study of distinct serum proteomics for the biomarkers discovery in colorectal cancer.

Predicting Metachronous Liver Metastasis From Colorectal Cancer Using Serum Proteomic Fingerprinting

Proteomics-Based Identification of Candidate Exosomal Glycoprotein Biomarkers and Their Value for Diagnosing Colorectal Cancer

Proteomics study of colorectal cancer and adenomatous polyps identifies TFR1, SAHH, and HV307 as potential biomarkers for screening

Identification of metastasis-associated exoDEPs in colorectal cancer using label-free proteomics

Quantitative proteome analysis of tumor markers associated with colorectal cancer

2D-DIGE-MS Proteomics Approaches for Identification of Gelsolin and Peroxiredoxin 4 with Lymph Node Metastasis in Colorectal Cancer

[Application of SELDI-TOF-MS in Detection of Liver Metastasis from Colorectal Cancer].

Molecular Characterization of Advanced Colorectal Cancer Using Serum Proteomics and Metabolomics

Discovery and Identification of Serum Potential Biomarkers for Colorectal Cancer Using TMT Quantitative Proteomics

Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components

Serum Exosomal Mir-122 As a Potential Diagnostic and Prognostic Biomarker of Colorectal Cancer with Liver Metastasis

Identification of Breast Cancer Metastasis‐associated Proteins in an Isogenic Tumor Metastasis Model Using Two‐dimensional Gel Electrophoresis and Liquid Chromatography‐ion Trap‐mass Spectrometry